1,023 research outputs found
MUARC Insight Webinar | Emeritus Professor Claes Tingvall - 01 May 2025
No full text<p dir="ltr">In 2025, Professor Claes Tingvall was appointed an Emeritus Professor of Monash University in recognition of distinguished academic service, and a testament to his immense contributions to traffic safety and injury prevention. Professor Tingvall is renowned for his work on the Vision Zero initiative, the Global Safety Footprint, and his involvement in the creation of the road safety ISO certification, ISO 39001.</p><p dir="ltr">His expertise has been instrumental in shaping global traffic safety standards and fostering strong collaborations between Australia and Sweden. Having been involved with MUARC since his Directorship (1998-2001), Professor Tingvall has continued to contribute as an Adjunct Professor, collaborating on research projects and mentoring staff. His extensive leadership and deep knowledge continue to inspire our work, and we are honoured to have him as part of our community.</p><p dir="ltr">In this <b>MUARC </b><b><i>Insight</i></b><b> webinar</b> held on 01 May 2025, hear Professor Tingvall share insights from his distinguished career and the pioneering work on the Road Safety Ministerial conferences in 2020 and 2025, ISO 45001 certification, and the FIA Road Safety Index.</p><p dir="ltr">The webinar is hosted by MUARC Director, Professor Stuart Newstead, and features an audience Q&A with Emeritus Professor Claes Tingvall after his presentation.</p>
Claes Oldenburg : Raw Notes : Documents and Spirits of the Performances : "Stars", "Moveyhouse", "Massage", "The Typewriter" with Annotations by the Author
No full textReproduces Oldenburg's complete unaltered collection of documents (including scripts, notes, instructions, theory) relating to four performances dating from 1963-1968, transcribed from their original form. Includes annotations by the author and examples of the original manuscripts
Claes Nobel, an international environmental activist and a member of the Swedish
No full textClaes Nobel, an international environmental activist and a member of the Swedish family that sponsors the Nobel Prize, was guest speaker yesterday at the Maine Alliance meeting that was held in Portland\u27s State Theatre. Nobel urged Maine business leaders to respect the environment and warned of the disasters that could befall mankind if the warning is unheeded
When do we need clinical endpoint adjudication in clinical trials?
No full textClinical endpoint adjudication (CEA) is a standardized process for assessment of safety and efficacy of pharmacologic or device therapies in clinical trials. CEA plays a key role in many large clinical trials with the aim of achieving consistency and accuracy of the study results, by applying independent and blinded evaluation of suspected clinical events reported by investigators. However, due to high costs there are different opinions regarding the use of central adjudication versus more simplified strategies or site-based assessments and whether the final results differ significantly. There is a lack of scientific evaluation of different adjudication strategies, and more knowledge is needed on the optimal adjudication process and how to achieve the best cost-effectiveness. New methodologies using national registry data and artificial intelligence may challenge the traditional adjudication strategy and could potentially reduce cost considerably with a similar result. Further research and evidence in this field of clinical trials methodology are essential
Claes Oldenburg : Multiples 1964-1990 /
No full textCatalog of an exhibition held at the Portikus, Frankfurt am Main, Feb. 22-Mar. 31, 1992; Lenbachhaus München, Apr. 8-May 10, 1992; and Hochschule für angewandte Kunst in Wien, Oct. 6-Nov. 21, 1992.Includes bibliographical references (p. 94)
Lease of land from Hilletje Jans, widow of Ide Cornelius Van Vorst, to her son-in-law Jan Ariense Sip, 1694
No full textDocument in which Hilletje Jans, widow, asserts that she has leased a tract of land to her son in law Jan Arianse Sip, and agrees to continue the lease until her death, at which point all of her land is to be divided among her heirs, with certain exceptions detailed in document. Deed recorded by Town Clerk Claes Arentse Toers.Deed in Colonial Dutch from 1694, with transcription and translatio
This time I’m (not) voting: how campaign factors affect European citizens’ turnout in EP elections
No full textTurnout in European Parliament elections declined in every vote held between 1979 and 2014. Ahead of the 2019 elections, the EU launched an initiative, ‘This time I’m voting’, in the hope of raising public interest. While turnout did increase in the 2019 contest, it remains an open question as to whether such campaign efforts help mobilise citizens. Drawing on a new study, Franziska Marquart, Andreas C. Goldberg and Claes H. de Vreese assess the role of individuals’ passive exposure to and active engagement with the 2019 campaign, finding that not all campaign efforts helped to increase turnout, with some even serving to demobilise the European electorate
Should we consider early de-escalation of maintenance dose of antiplatelet therapy post-ACS?
No full textLessons from platelet inhibition and patient outcomes
No full textPurpose of review Ticagrelor is a new, direct acting, reversibly binding P2Y12 receptor antagonist with more potent inhibition of platelets than clopidogrel and which does not require metabolic activation. It was compared with clopidogrel, on a background of the standard of care in a randomized trial in the Platelet Inhibition and Patient Outcomes (PLATO) study, on patients with acute coronary syndrome (ACS). The purpose was to evaluate the efficacy and safety results from the global, prospective trial in a broad population [ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) patients] with ACS. Recent findings The main findings were a significant reduction of the primary outcome (death from vascular causes/myocardial infarction/stroke) with ticagrelor versus clopidogrel [9.8 versus 11.7% (hazard ratio 0.84; 95% confidence interval: 0.77-0.92); P<0.001] without a significant increase in PLATO-defined major bleeding (11.6 versus 11.2%, respectively; P = 0.43), but a higher occurrence of noncoronary artery bypass grafting (CABG) related major bleeding (4.5 versus 3.8%; P = 0.026). In addition, there was a significant reduction in vascular mortality (4.0 versus 5.1%; P = 0.001). The findings were consistent in all subgroups, such as for STEMI, NSTEMI, planned invasive or noninvasive strategy, diabetes, renal function, and CABG. Summary Among patients with an ACS with or without ST-segment elevation, treatment with ticagrelor, as compared with clopidogrel, significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of nonprocedure-related bleeding.</p
Editorial commentary : Emotional distress in women after acute myocardial infarction – still a long way to walk
No full text- …
